Search

Displaying results 611 - 620 of 1723 in total
  1. Drug

    Primidone

    go.drugbank.com/drugs/DB00794
    ApprovedVet approved

    [A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112]

  2. Drug

    Cisapride

    go.drugbank.com/drugs/DB00604
    ApprovedWithdrawn

    The FDA issued a warning letter regarding this risk to health care professionals and patients.

  3. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [A189165] The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis

  4. Drug

    Certolizumab pegol

    go.drugbank.com/drugs/DB08904
    ApprovedInvestigational

    [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]

  5. Drug

    Terbutaline

    go.drugbank.com/drugs/DB00871
    ApprovedInvestigational

    [A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088]

  6. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  7. Drug

    Potassium bitartrate

    go.drugbank.com/drugs/DB11107
    ApprovedInvestigational

    Potassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120] … Approved by the FDA as a direct food substance, potassium bitartrate is used as an additive, stabilizer, pH control agent, antimicrobial agent, processing aid, or thickener in various food products [L2732

  8. Drug

    Teprotumumab

    go.drugbank.com/drugs/DB06343
    ApprovedInvestigational

    approved by the FDA in January 2020 for the treatment of TED. … [L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was

  9. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia). … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with

  10. Drug

    Triamcinolone

    go.drugbank.com/drugs/DB00620
    ApprovedInvestigationalVet approved

    [L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. … [L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients